Summary & Overview
HCPCS Level II J8610: Methotrexate, Oral, 2.5 mg
HCPCS Level II code J8610 denotes oral methotrexate in 2.5 mg unit doses, a commonly used formulation for oncology, rheumatology, and dermatology indications. Nationally, accurate coding for unit-dosed oral methotrexate matters for medication reimbursement, inventory tracking, and clinical documentation. This code supports billing for dispensed oral medication rather than parenteral administration.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J8610 is used in clinical workflows and claims, typical sites of service, and payer coverage considerations. The publication summarizes benchmarkable elements such as unitization practices and billing scenarios, highlights relevant policy updates affecting oral chemotherapy and pharmacy-dispensed medications, and provides clinical context for common uses of low-dose methotrexate.
The content is intended for coding professionals, revenue cycle staff, pharmacists, and clinical leaders who need a clear reference for the code’s clinical meaning, billing context, and payer landscape at a national level. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J8610 represents Methotrexate, oral, 2.5 mg. The service is the provision of an oral formulation of methotrexate in 2.5 mg unit doses. The service type is medication administration / pharmacy-dispensed oral chemotherapy or immunomodulatory therapy. The typical site of service is outpatient pharmacy dispensing or outpatient clinic administration for oral self-administration.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic inflammatory or rheumatologic condition (for example, rheumatoid arthritis, psoriasis with psoriatic arthritis, or inflammatory bowel disease) who is prescribed low-dose oral methotrexate for disease control. The medication is dispensed in 2.5 mg tablets and billed under J8610 per tablet. Clinical workflow begins with a specialty clinic visit (rheumatology, dermatology, or gastroenterology) where the clinician documents the indication, planned dose and schedule (commonly weekly), baseline laboratory evaluation (CBC, liver function tests, creatinine), and patient counseling on dosing and folic acid supplementation. Prior authorization may be obtained from the patient’s payor (examples: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare) when required. The pharmacy processes the prescription, dispenses the prescribed number of 2.5 mg tablets, and submits claims using J8610 with appropriate modifiers to indicate payment circumstances (e.g., outpatient administration, ordering provider status, or billing adjustments). Follow-up includes periodic lab monitoring, dose adjustments, and documentation of adverse effects or treatment response in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |